Technical Analysis for VTYX - Ventyx Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.15 | -0.46% | -0.01 |
Earnings due: Nov 4
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -2.71% | |
| Fell Below 50 DMA | Bearish | -2.71% | |
| MACD Bearish Signal Line Cross | Bearish | -2.71% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | -2.71% | |
| MACD Bullish Signal Line Cross | Bullish | -10.04% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 20 hours ago |
| Reversed from Up | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Gap Up Partially Closed | about 24 hours ago |
| Gapped Up (Partial) | about 24 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/04/2024
Ventyx Biosciences, Inc. Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Autoimmune Disease Inflammatory Diseases Psoriasis Inflammatory Bowel Disease Ulcerative Colitis Autoimmune Disorders Cytokine Lupus Immune Mediated Diseases Psoriatic Arthritis Molecule Product Inflammasome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.8 |
| 52 Week Low | 1.79 |
| Average Volume | 1,099,440 |
| 200-Day Moving Average | 3.56 |
| 50-Day Moving Average | 2.25 |
| 20-Day Moving Average | 2.26 |
| 10-Day Moving Average | 2.24 |
| Average True Range | 0.14 |
| RSI (14) | 45.05 |
| ADX | 18.19 |
| +DI | 25.56 |
| -DI | 21.48 |
| Chandelier Exit (Long, 3 ATRs) | 2.17 |
| Chandelier Exit (Short, 3 ATRs) | 2.46 |
| Upper Bollinger Bands | 2.57 |
| Lower Bollinger Band | 1.95 |
| Percent B (%b) | 0.32 |
| BandWidth | 27.22 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.018 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.30 | ||||
| Resistance 3 (R3) | 2.31 | 2.28 | 2.28 | ||
| Resistance 2 (R2) | 2.28 | 2.24 | 2.27 | 2.27 | |
| Resistance 1 (R1) | 2.21 | 2.21 | 2.20 | 2.20 | 2.26 |
| Pivot Point | 2.18 | 2.18 | 2.17 | 2.17 | 2.18 |
| Support 1 (S1) | 2.11 | 2.14 | 2.10 | 2.10 | 2.04 |
| Support 2 (S2) | 2.08 | 2.11 | 2.07 | 2.03 | |
| Support 3 (S3) | 2.01 | 2.08 | 2.03 | ||
| Support 4 (S4) | 2.00 |
